Posted inInfectious Diseases news Public Health
A Single Shot Against Rift Valley Fever? Phase 1 ChAdOx1 RVF Trial Shows Acceptable Safety and Robust Immune Responses in Uganda
In a randomized, placebo-controlled phase 1 trial in Uganda, a single intramuscular dose of ChAdOx1 RVF (adenovirus-vectored) was well tolerated and induced rapid T-cell responses and neutralising antibodies, supporting further evaluation of the 5×10^10-particle dose.